Whether you’re a customer, a job seeker, a health professional or an investor, the best way to contact our Belgian offices you can find below.
GlaxoSmithKline Pharmaceuticals SA/NV
Avenue Pascal, 2-4-6
Tel :+ 32 10 85 85 00
GlaxoSmithKline in Grand Duchy of Luxembourg
Hireknopf - Business Center
2-4, Parc d'Activités
Tel : +352 25 34 25
GlaxoSmithKline Biologicals SA (Vaccines)
Avenue Fleming 20
Tel: +32 10 85 51 11
rue de l’Institut 89
Tel: +32 2 656 81 11
GlaxoSmithKline Consumer Healthcare SA
Avenue Pascal, 2-4-6
Tel :+32 10 85 86 00
Privacy contact information
Details of GSK companies in the European Economic Area (EEA) and Switzerland, each of which acts as data controllers, can be found below. If you wish to contact GSK’s data protection officer, or to contact one of the GSK companies listed, please use the contact details provided.
If you wish to exercise any of your individual rights under data protection laws, please consult first the privacy notice provided to you when your personal information was collected. The appropriate contact details can be found under the heading “Your rights”.
Report an adverse event
For Belgium: Please report adverse events to the Belgian Centre for Pharmacovigilance for medicines for Human use (BCPH) of the Federal Agency for Medicines and Health Products (FAMHP) by following the procedure described on the website http://www.fagg-afmps.be or to GlaxoSmithKline Pharmaceuticals SA/NV at the number +32 (0)10 85 85 00.
For Luxembourg: Please report adverse events to Ministère de la Santé du Grand-Duché de Luxembourg (Division de la Pharmacie et des Médicaments at fax number +35 (0)2 24795615 or by post) or to Centre Régional de Pharmacovigilance de Lorraine (fax number +33 (0)3 83 32 33 44 or email@example.com) or to GlaxoSmithKline Pharmaceuticals SA/NV at number +32 (0)10 85 85 00.
Find out more
Are you looking for your next career move, or an internship? On these pages you'll find a wide range of opportunities.
Find and select a location to find out more about GSK around the world.
It is vital for us to continuously monitor the safety of our products. Share your experiences.
BE/COM/0014/15(2) Nov 2018